Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase.

Cancers (Basel) · 2022 · PMC8750394 · PMID 35008374

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Two independent public mRNA expression datasets from HR-positive EBC (210 patients from GSE26971 and 209 patients from GSE2034 ) showed a trend toward an association of PLK1 overexpression and a higher risk of distant recurrence ( Figure S4G ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.